Benefits of Utilizing Early Precision QT and Artificial Intelligence-Powered Data Quality Assessments in Early Phase Trials Webinar Replay

Presented by Clario’s cardiac safety experts, Dr. Vic Patel and Dr. Jean Philippe Couderc, the webinar will review the opportunities provided by FIH trials to detect and manage the safety signals of a new drug entity. The advantage of using EPQT to leverage data from small FIH trials, along with specific results of how EPQT can assess the risk of QT interval prolongation will be discussed. Finally, an overview of how the AI-powered data quality tool was developed and its ability to assess data quality will be presented. The session concludes with a Q&A, providing participants with an opportunity to engage directly with the experts.

What you’ll learn:

• Review the importance of the first-in-human trial and the opportunities it affords
• Understand the advantage of leveraging EPQT and AI-powered data quality in early-phase QT assessment